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The emergence of bacterial strains resistant to most of the clin-
ically useful antibiotics has provided the impetus to develop
new classes of antibiotics that might combat bacterial resist-
ance more effectively. Antimicrobial peptides (AMPs) are small
peptides (typically 15–30 residues) that show promise as thera-
peutic agents against bacteria, fungi, and viruses.[1–3] Widely
distributed in plants and animals, they form part of the innate
immune system’s defense against microbes. Although highly
diverse in sequence and structure, almost all AMPs share the
property of being highly amphiphathic: one face of the pep-
tide is hydrophobic and the other face presents a cluster of
positively charged residues.[4,5] AMPs function by disrupting
bacterial membranes,[4] which contain predominantly negative-
ly charged phospholipids. Eukaryotic membranes, which con-
tain predominantly neutral phospholipids, are not targeted.
Although promising as broad-spectrum antibiotics, AMPs are
susceptible to proteolysis in vivo by endogenous or bacterial
proteases, which can considerably diminish their effectiveness.
Attempts to overcome this problem by increasing the dose of
AMP often leads to toxic side effects, most notably lysis of red
blood cells, which has been attributed to nonspecific hydro-
phobic interactions between the peptide and the eukaryotic
cell membrane.[6,7] Here we describe a strategy to overcome
these limitations, by exploiting the unusual physicochemical
properties exhibited by fluorocarbons.
Fluorocarbons are noted for their chemical inertness and
their extreme hydrophobicity. Fluorocarbon solvents exhibit
unusual self-segregating properties, known as the fluorous
effect, which has been exploited in organic synthesis to facili-
tate the extraction of organic molecules “tagged” with fluoro-
carbon chains from organic solvents.[8] Work in our laboratory
and others has shown that extensively fluorinated analogues
of leucine and valine can significantly stabilize small proteins
against thermal and chemical denaturation,[9–15] an effect that
can be attributed to the extremely hydrophobic nature of fluo-
rocarbons. Although fluorinated amino acids have been incor-
porated into AMPs,[16] so far extensively fluorinated or fluorous
amino acids have not been used to modify the biological prop-
erties AMPs. We reasoned that if these properties of fluoro-
ACHTUNGTRENNUNGcarbons could be designed into AMPs, then the expected in-
creased structural stability might provide resistance to proteol-
ysis, without abolishing their biological activity or increasing
their toxicity to eukaryotic cells.
To test this concept we have synthesized a fluorous ana-
logue of the potent and well-characterized AMP, MSI-78 (also
called pexiganan). MSI-78 is a synthetic analogue of magainin-
2, an a-helical AMP originally isolated from Xenopus laevis, that
has potent antibacterial activity.[17,18] The peptide is unstruc-
tured in free solution but forms a dimeric antiparallel a-helical
coiled-coil on association with lipid bilayers[19] (Figure 1) and is
believed to exert its antibacterial effect by forming toroidal
pores in the bacterial membrane.[20] We have replaced the two
leucine and isoleucine residues in MSI-78 with the fluorous
amino acid l-5,5,5,5’,5’,5’-hexafluoroleucine (hFLeu) to produce
a molecule we call fluorogainin-1 (Figure 1). The sequences of
these peptides are shown below (where X=hFLeu):
MSI-78: GIGKFLKKAKKFGKAFVKILKK
fluorogainin-1: GXGKFXKKAKKFGKAFVKXXKK
We have compared the antimicrobial activity, hemolytic activi-
ty, and resistance to proteolysis of fluorogainin-1 and MSI-78.
We have also examined the interactions of these peptides with
lipids using isothermal titration calorimetry (ITC).
Fluorogainin-1 was synthesized manually by using Boc-pro-
tected amino acids by standard protocols ;[21] Boc-protected
hFLeu was synthesized as described previously.[22] As a control,
MSI-78 was synthesized by standard automated methods as
described previously.[23] Both peptides were purified by re-
versed-phase HPLC and their identities confirmed by MALDI-
MS.
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Figure 1. Left : Structure of MSI-78 dimer showing Leu and Ile residues in
CPK rendering. Center: View along the helical axis of MSI-78 dimer showing
disposition of Lys residues. Right: model of fluorogainin-1 based on struc-
ture of MSI-78 showing hFleu residues in CPK rendering.
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We first compared the effect of fluorination on the antimi-
crobial activity of the two peptides. The minimum inhibitory
concentration (MIC) of MSI-78 and fluorogainin-1 were deter-
mined by the microdilution antimicrobial assay procedure, as
described previously.[24] A panel of eleven bacterial strains were
chosen that included both Gram positive and Gram negative
strains of common pathogenic bacteria. Twofold serial dilu-
tions of each AMP were made into cultures of each bacterial
strain and the minimum concentration needed to prevent bac-
terial growth was determined. The results are summarized in
Table 1.
The fluorous AMP retained the broad-spectrum an-
tibiotic ACHTUNGTRENNUNGactivity of MSI-78, even though the incorpora-
tion of eight trifluoromethyl groups into the peptide
might be considered quite an extensive modification
of the structure. Although MSI-78 appeared slightly
more active than fluorogainin-1 against many of the
bacteria, differences of twofold in MIC cannot be
considered statistically significant in this type of dilu-
tion assay. However, fluorogainin-1 was significantly
more potent (p<0.05) against two important patho-
genic bacteria : the MIC of fluorogainin-1 against Kleb-
siella pneumoniae was 16 mgmL1 whereas MSI-78
showed no activity, and the MIC of fluorogainin-1
was approximately four-times lower than MSI-78
against Staphylococcus aureus. The only bacterium
tested for which fluorogainin-1 was significantly (p<
0.05) less effective than MSI-78 was Streptococcus
pyogenes.
To determine whether fluorination might result in increased
toxicity, the hemolytic activity of both AMPs was tested against
sheep erythrocytes by using a standard lysis assay for hemo-
globin release from erythrocytes as described previously.[25]
Neither MSI-78 nor fluorogainin-1 exhibited any hemolytic ac-
tivity at concentrations of up to 250 mgmL1. To place this
result in context: many AMPs exhibit hemolytic activity at con-
centrations well below 100 mgmL1. It appears, therefore, that
even though the hFLeu side chain is considerably more hydro-
phobic than Leu or Ile[12] this does not result in the peptide
binding to erythrocyte membranes.
The secondary structure of the peptides was examined by
CD spectroscopy. Peptide samples were prepared at 70 mm
concentration in Tris-Cl buffer (100 mm), CaCl2 (10 mm), pH 7.8,
at 25 8C. In the absence of liposomes both peptides were un-
structured (data not shown), which is consistent with their
being highly positively charged. However, in the presence of
small unilamellar vesicles (SUVs) prepared from 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphotidylcholine (POPC, 14 mm final
concentration) both peptides exhibited CD spectra characteris-
tic of an a-helical structure (Figure 2). Interestingly, fluorogai-
nin-1 appeared significantly less helical than MSI-78 as judged
by the CD spectra, with a mean residue ellipticity at 222 nm of
only about 2=3 that of the nonfluorinated peptide. This is in
accord with recent studies that have shown that hFLeu has a
poor helix propensity,[26] despite the fact that it has been
found to stabilize a-helical proteins against unfolding.
We next examined the stability of fluorogainin-1 and MSI-78
towards proteolysis by two common proteases, trypsin, and
chymotrypsin. These proteases provide a stringent test for
structural stability as both peptides have multiple potential
cleavage sites for both enzymes. Peptides (350 mm) were dis-
solved in Tris-Cl buffer (100 mm), CaCl2 (10 mm), pH 7.8, and
were incubated in the presence of POPC (15 mm) liposomes
and protease (1.25%, w/w) at 25 8C for various times and the
extent of proteolysis was determined by reverse phase HPLC.
Under these conditions MSI-78 was almost completely degrad-
ed by either protease within 30 min, however, fluorogainin-1
showed no signs of degradation even after 10 h (Figure 2). In
the absence of liposomes, when the peptides are unstructured,
both peptides were equally rapidly degraded by both trypsin
and chymotrypsin. Therefore, it appears that the resistance of
fluorogainin-1 to proteolysis is due to its interaction with lipo-
somes and not because the incorporation of hFLeu per se pre-
vents the peptide from being digested by proteases.
The interactions between liposomes and the AMPs were
studied by isothermal titration calorimetry. Measurements were
made under conditions similar to those used to study the
Table 1. MICs of MSI-78 and fluorogainin-1 against various bacterial
strains.
Bacterial strain MIC [mgmL1]
MSI-78 fluorogainin-1
Bacillus subtilis <4 8
Kocheria rhizophila <4 8
Enterobacter aerogenes >250 >250
Klebsiella pneumoniae >250 16[a]
Proteus mirabilis >250 >250
Salmonella enteritis 16 32
Streptococcus pyogenes 8 62[b]
Escherichia coli (DH5a) <4 8
Staphylococcus aureus (UH-11) 62 16[a]
Shigella sonnei 16 32
Enterococcus fecaelis (OG1X) >250 >250
[a] MIC of fluorogainin-1 was significantly lower than that of MSI-78 (p<
0.05); [b] MIC of fluorogainin-1 was significantly higher than that of MSI-
78 (p<0.05).
Figure 2. A) CD spectra for MSI-78 (*) and fluorogainin-1 (*) in the presence of POPC.
B) Stability of MSI-87 (grey) and fluorogainin-1 (white) towards digestion with trypsin
(solid bars) or chymotrypsin (dotted bars).
ChemBioChem 2008, 9, 370 – 373 G 2008 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim www.chembiochem.org 371
binding of the parent peptide magainin-2 to SUVs.[27] SUVs
were freshly prepared from a 3:1 (mol/mol) mixture of POPC/
POPG (final concentration 15 mm) in potassium phosphate
buffer (12 mm, pH 7.4) containing NaCl (137 mm), thoroughly
degassed, and introduced into the calorimeter cell. A solution
of peptide (200 mm ; dissolved in the same buffer) was injected
in 4 mL increments into the liposome solution. Measurements
were made at 25 8C by using a Microcal VP calorimeter. Heats
of dilution were determined by injecting peptide solutions into
buffer that lacked SUVs and subtracted from the raw data.
The thermograms for each peptide binding to liposomes are
shown in Figure 3. The enthalpies (calculated from the peak
areas of each injection of peptide) for each peptide bound to
the lipids were similar : DH for MSI-78 was (14.40.2) kcal
mol1, whereas DH for fluorogainin-1 was slightly less exother-
mic at (12.50.3) kcalmol1. These enthalpies are similar to
those measured previously for magainin-2 peptide bound to
SUVs.[27] The titration of fluorogainin-1 appears to have a slight
increase in heat released with increasing injection number; this
indicates some dependence on peptide concentration, al-
though the significance of this is unclear. The enthalpic contri-
bution to liposome binding has been determined to arise pri-
marily from electrostatic interactions between the positively
charged peptide and negatively charged lipid head groups.[27]
Since MSI-78 and fluorogainin-1 contain identical cationic resi-
dues, the electrostatic interactions are expected to be very
similar. This result strongly suggests that the increase in hydro-
phobicity imparted by the fluorous residues is primarily re-
sponsible for modifying the biological properties of fluorogai-
nin-1.
In conclusion, by introducing fluorous amino acid residues
into an AMP we have conferred almost complete resistance to
proteolysis of the fluorous AMP under conditions in which the
nonfluorinated AMP is rapidly degraded, while retaining the
broad spectrum of antimicrobial activity. Protection against
proteolysis was only observed in the presence of liposomes;
this suggests that lipid–peptide interactions are important.
MSI-78 has been shown to dimerize to form a coiled-coil in a
membrane environment.[19] Based on this observation, one
plausible explanation of the protease resistance exhibited by
fluorogainin-1 is that incorporation of the more hydrophobic
hFLeu side chain strengthens the hydrophobic interactions be-
tween AMP dimers, just as we have demonstrated for other
coiled-coil proteins.[12,13] This would, in turn, promote the for-
mation of structured dimers that are resistant to proteolysis.
It is also noteworthy that fluo-
rogainin-1 shows a selectivity to-
wards bacterial strains that are
slightly different from that of
MSI-78. Fluorogainin-1 exhibited
significantly improved potency
against K. pneumoniae and
S. aureus, with MICs of
16 mgmL1 against both bacteria.
Although the selectivity of AMPs
for some bacteria and not others
is poorly understood,[6] it is
known that the resistance of
S. aureus to AMPs is due, at least
in part, to secretion of proteas-
es.[28] The resistance of fluorogai-
nin-1 to proteolysis might ex-
plain its improved potency
against this important bacterial
pathogen.
More generally, our results
suggest the strategy of incorpo-
rating fluorous residues into bio-
logically active membrane-asso-
ciated peptides could be used to enhance the efficacy or mod-
ulate the activity of other biologically important peptides. For
example, membrane-active peptides are known to be impor-
tant in membrane fusion and ion-channel formation, and have
also been found to have anticancer and antiviral activities.[29–32]
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